TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

Mobile site search icon.
Mobile navigation icon.

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

Lexi
Real TAKHZYRO patient

REIMAGINE YOUR LIFE WITH HAE

TAKHZYRO is a first-of-its-kind medicine used to prevent
attacks of hereditary angioedema (HAE) in people 12 years of
age and older.

See What's Possible

See Lexi's
Reimagine Story

Down arrow icon.

Reimagine your life with fewer attacks

Fewer attacks or zero attacks for period of time in the clinical studies

People taking TAKHZYRO in 2 clinical studies, a 6.5-month
study and a 2.5-year, open-label extension study, had HAE
attacks less often. Some people in the studies had
zero attacks. Want to see the details?

In a 6.5-month clinical study of 125 people with HAE 12 years of age and older, TAKHZYRO significantly reduced the number of monthly attacks, compared with placebo. People taking TAKHZYRO also had fewer moderate or severe attacks and fewer attacks requiring acute treatment, compared with placebo. And according to a supportive analysis, there were people taking TAKHZYRO who had zero attacks during the entire clinical trial. In the 2.5-year, long-term, open-label extension study with 212 people with HAE, people taking TAKHZYRO had similar results compared with baseline. Baseline means a person's attack rate before beginning treatment in either the 6.5-month clinical trial or the long-term, open-label study. Long term safety of TAKHZYRO was the primary endpoint in the open-label extension study.

More Study Info

TAKHZYRO may cause serious side effects, inclduing allergic reactions.

See Marie's
Reimagine Story

Calendar icon. TAKHZYRO® injection is taken every two weeks.

Reimagine your
dosing schedule

TAKHZYRO is a subcutaneous (under-the-skin)
injection you give yourself just once every 2 weeks
after being trained by a healthcare provider.

GET DOSING INFO

The recommended dose is 300 mg every 2 weeks for people starting on TAKHZYRO. If you have zero attacks for more than 6 months, your doctor may consider prescribing TAKHZYRO 300 mg every 4 weeks.

See what made patients
want to start TAKHZYRO

Speech bubbles icon.

Ready to ask your doctor about TAKHZYRO?

Curious about what TAKHZYRO could do for you? Ask
your doctor. You can use our discussion guide to help
get the conversation started.

start your guide

OnePath® icon.

Personalized product support every step of the way

OnePath® helps people who have been prescribed TAKHZYRO per the approved indication get access to their medication.